Company profile
PepGen Inc. logo

PepGen Inc.

Pipeline5 assets

Latest news8 items

All news

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

BOSTON --(BUSINESS WIRE)--May 21, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its

Presentation / AbstractIDMC-15 poster presentation Wed, May 27, 2026, 10:45 AM EDT

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as

Enrollment • Phase 2Enrollment milestone Tue, Mar 31, 2026

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing

Trial Results • Phase 2

PepGen Announces Regulatory Updates on FREEDOM2

- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing of the 10 mg/kg cohort continues in the UK and Canada - - PepGen reiterates

PepGen to Participate in the Leerink Global Healthcare Conference

BOSTON --(BUSINESS WIRE)--Mar. 3, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur,

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

BOSTON --(BUSINESS WIRE)--Dec. 8, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of

PepGen Inc. • Endpoint Arena